Godavari Biorefineries Secures Global Patent for Promising Cancer Compound

Godavari Biorefineries Ltd has received patent validation from the China National Intellectual Property Administration (CNIPA) for its novel anti-cancer molecule, adding to recent approvals across Spain, the UK, and the European Union. This marks a major milestone in the company’s push into biotech innovation alongside its core bio-based chemical business.

 

Key Highlights:

 

- The patented compound has shown efficacy against both cancer cells and cancer stem cells, with potential applications in treating breast and prostate cancers.

- Preclinical animal studies have demonstrated encouraging safety and effectiveness, and the molecule is currently undergoing Phase 1a clinical trials involving patients with advanced solid tumors and healthy volunteers.

- The patent strengthens Godavari’s intellectual property portfolio and global footprint in oncology research.

 

Biotech Expansion:

- The molecule was developed under Godavari’s clinical-stage biotech division, Sathgen Therapeutics, which is also working on antiviral therapies.

- The company exports to over 20 countries and maintains active collaborations with international research institutions.

- This development reflects Godavari’s growing investment in translational research aimed at addressing critical global health challenges.

 

Strategic Outlook:

- With patent protection now spanning Europe and China, Godavari is positioned to attract global partnerships and funding for further clinical development.

- The company’s diversification into advanced therapeutics complements its leadership in ethanol, renewable chemicals, and agricultural feedstock-based materials.

 

Sources: CNBC TV18, HealthCare Radius, HDFC Sky, BioVoice News, Godavari Biorefineries Official Website